ConferenceInfectious Diseases Society of America. It brings together scientists, clinicians, innovators and cross-sector leaders working to address antimicrobial resistance.
The meeting covers the antimicrobial innovation pipeline from fundamental resistance research to clinical translation. Its scientific scope includes emerging resistance mechanisms, adaptive microbial responses, host–pathogen interactions, antimicrobial targets, drug discovery, pharmacokinetics and pharmacodynamics, novel diagnostics and early clinical studies.
IMARI also examines how discoveries can progress from laboratory research towards new treatments and diagnostic approaches. Sessions address areas such as target validation, chemical and synthetic biology, artificial intelligence in molecule design, target product profiles, funding models and non-traditional approaches to antimicrobial resistance.
By connecting participants from academia, clinical practice, biotechnology, the pharmaceutical industry, government and research funding organisations, IMARI supports collaboration across the antimicrobial research and development community. The meeting is relevant to researchers, clinicians, drug and diagnostic developers, industry representatives and public-health stakeholders involved in antimicrobial resistance and innovation.